APOB and coronary artery disorder: In contrast to LDLR-pathway drugs, genetically predicted LPL pathway targeting scaled on apoB levels have heterogeneous associations with CAD, suggesting that the association of the LPL pathway with CAD is not entirely explained by apoB lowering6.